Which hedge funds own EPRX? EUPRAXIA PHARMACEUTICALS INC, Q2 2026 13F holders
26 tracked hedge funds disclosed a position in EPRX (EUPRAXIA PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $85.2m in total. The largest holder by portfolio weight is Ally Bridge Group (NY) LLC at 2.1% of its book. 8 opened a new position this quarter: DAFNA Capital Management LLC, Stonepine Capital Management, LLC, Orbimed Advisors LLC, Lynx1 Capital Management LP. 3 exited: Squadron Capital Management LLC, Diadema Partners LP, Hudson Bay Capital Management LP.
- 26
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 8
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 3
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $7.0m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $5.9m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $85.2m
- Combined value Sum of the holders' reported positions in the security.
- 2.1%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Squadron Capital Management LLC | 2.0% | $4.9m |
| Diadema Partners LP | 0.1% | $290k |
| Hudson Bay Capital Management LP | 0.0% | $669k |
Ownership over time
Who discovered EPRX first? Beta
| Ally Bridge Group (NY) LLC | Q3 2025 | +0.7 pts |
| Great Point Partners LLC | Q3 2025 | +0.5 pts |
| Ikarian Capital, LLC | Q1 2026 | −0.1 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.